Image: The ADVIA Centaur XP (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany) has announced that it will invest around USD 300 million over a four-year period for expanding its laboratory diagnostics manufacturing and research and development facility located in Walpole, Massachusetts in the US.
Siemens Healthineers focuses on the therapeutic and molecular diagnostic market, and offers medical imaging, laboratory diagnostics, and management, consulting and digital services. The company’s laboratory diagnostics unit in Massachusetts is its main facility used for manufacturing assays that run on the ADVIA Centaur family of immunoassay instruments, as well as consumables for its molecular and blood gas testing instruments. The company also plans to use the facility for manufacturing assays that will run on the immunoassay module of the Atellica Solution, which is currently under FDA review.
The company now plans to upgrade and expand the existing facility with renovations scheduled to begin in the coming weeks. The facility’s expansion, which will include manufacturing, warehouse, office and lab space, is scheduled to begin in the summer.
“The expansion of the Walpole facility fits into the strategic growth plans for the company and allows us to increase our manufacturing footprint in the United States, the largest healthcare market in the world,” said Bernd Montag, Chief Executive Officer, Siemens Healthineers. “The laboratory instruments and reagents developed and manufactured at the Siemens Healthineers Walpole facility impact patients and healthcare providers across the globe.”